Acadia Pharmaceuticals Expects Over $1 Billion in 2025 Sales, Driven by Strong Growth in CNS Disorders and Rare Diseases Market

Acadia Pharmaceuticals projects net sales to exceed $1 billion by 2025, indicating strong growth expectations. The company operates in the biotechnology sector, focusing on CNS disorders and rare diseases, and demonstrates robust financial health with a strong balance sheet and high profitability margins. Acadia's current trading metrics reveal a P/E ratio of 17.07, a P/S ratio of 4.23, and a P/B ratio of 4.88, which are close to their respective one-year highs, indicating that the stock may be fairly valued at current levels.